Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. In this podcast, dr. Lisa Salvatore discusses the primary analysis results of the phase II AVANA study, which
    evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced
    rectal cancer

2. Adjuvant nab-paclitaxel plus gemcitabine prolongs survival in resected pancreatic cancer

3. No benefit from adding napabucasin to FOLFIRI in patients with previously treated metastatic colorectal
    cancer

4. The MODUL study: biomarker-driven maintenance therapy following first-line standard induction treatment
    of metastatic colorectal cancer

5. Pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for unresectable or metastatic
    HER2-positive gastric or GEJ adenocarcinoma